Amgen Inc. $AMGN Stock Holdings Raised by MGO One Seven LLC

Key Points

• MGO One Seven LLC increased its Amgen stake by 74.9% in the third quarter, bringing its holdings to 21,758 shares valued at approximately $9.17 million. Institutional investors collectively own 76.5% of the company.
• Amgen shares opened at $466.01, near their 52-week high of $475.65, after reporting quarterly EPS and revenue above analyst expectations. The company also declared a quarterly dividend of $2.52, or $10.08 annualized, yielding about 2.2%.
• Insiders have been net sellers: Two senior vice presidents sold a combined 4,222 shares for roughly $1.72 million, while insiders sold 6,222 shares worth $2.54 million over the past three months. Analysts remain mixed, with a consensus “Hold” rating and a $389.71 price target.

MGO One Seven LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 74.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,758 shares of the medical research company's stock after buying an additional 9,321 shares during the quarter. MGO One Seven LLC's holdings in Amgen were worth $9,171,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rational Advisors Inc. lifted its stake in shares of Amgen by 13.7% in the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company's stock worth $72,000 after buying an additional 24 shares in the last quarter. Beacon Financial Advisory LLC grew its stake in Amgen by 2.0% during the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company's stock valued at $461,000 after acquiring an additional 25 shares in the last quarter. James T. Borello RIA grew its stake in Amgen by 13.6% during the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company's stock valued at $88,000 after acquiring an additional 25 shares in the last quarter. Sweeney & Michel LLC grew its stake in Amgen by 0.5% during the 3rd quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company's stock valued at $2,162,000 after acquiring an additional 25 shares in the last quarter. Finally, Legacy Financial Advisors Inc. raised its holdings in Amgen by 0.8% in the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company's stock valued at $1,234,000 after acquiring an additional 26 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Dividend support: Amgen’s dividend announcement helped reinforce the stock’s income appeal and contributed to its move to a new 1-year high. Amgen Sets New 1-Year High Following Dividend Announcement
• Positive Sentiment: Analyst endorsement: RBC Capital reaffirmed its Buy rating, providing continued Wall Street support ahead of the earnings release. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Pipeline and rare-disease progress: New Phase 3 dazodalibep data in Sjögren’s disease, UPLIZNA updates and a rare-disease diagnostic collaboration support Amgen’s longer-term growth narrative beyond its established products. Rare Disease Updates
• Neutral Sentiment: Key near-term catalyst: Amgen will report third-quarter 2026 results after the market close on November 3. The current consensus EPS estimate cited in previews is $5.79, making earnings, guidance and management commentary important tests for the recent rally. Amgen Q3 2026 Preview
• Negative Sentiment: Profitability concerns: Management has warned of rising expenses, while MariTide development is consuming substantial cash. Investors are watching whether growth from Repatha and TEZSPIRE can offset higher costs and protect margins. Amgen Faces Rising Expenses Ahead of Q3 Results
• Negative Sentiment: Valuation and execution risk: A skeptical earnings preview highlights concerns about the CFO transition, spending growth and whether Amgen can meet expectations after a substantial year-to-date advance. Amgen Earnings Preview

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 1,252 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by corporate insiders.

Amgen Price Performance

AMGN stock opened at $466.01 on Monday. The company's 50 day moving average price is $419.96 and its 200 day moving average price is $374.79. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $475.65. The firm has a market capitalization of $251.94 billion, a price-to-earnings ratio of 28.96, a PEG ratio of 3.41 and a beta of 0.43.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm's quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 22.96 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen's dividend payout ratio is currently 62.65%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Weiss Ratings upgraded Amgen from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 8th. Argus upped their target price on Amgen from $375.00 to $460.00 and gave the company a "buy" rating in a report on Wednesday, August 19th. Barclays raised their target price on Amgen from $380.00 to $400.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 21st. BMO Capital Markets reduced their price target on Amgen from $450.00 to $415.00 and set a "market perform" rating on the stock in a report on Monday, October 12th. Finally, Scotiabank boosted their price target on shares of Amgen from $450.00 to $500.00 and gave the company an "outperform" rating in a research report on Monday, September 28th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Amgen has a consensus rating of "Hold" and a consensus price target of $389.71.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.